Atsena Therapeutics key facts
as of Oct 2026- Developer of ocular gene therapies designed to reverse or prevent blindness.
- Atsena Therapeutics is valued at approximately $340.0M as of Oct 2026, set at its later-stage round, Apr 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $237.7M across 4 recorded rounds; the latest was Later Stage VC ($90.0M) in Mar 2025.
- Notable investors include Wellington Management, Bain Capital, Osage University Partners, Hatteras Venture Partners, Lightstone Ventures — 12 tracked in total.
- Atsena Therapeutics has filed 4 Form Ds with the SEC since 2020, most recently Apr 2025 ($90.0M sold to 14 investors).
- Status: Privately Held (backing).
Valued at $340.0M at its later-stage round, Apr 2025. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch Atsena Therapeutics: the Monday email on marks, rounds and moves
Atsena Therapeutics funding rounds
4 roundsWho backs Atsena Therapeutics
12+Membership and data by Private Market View
Atsena Therapeutics valuation
Atsena Therapeutics was valued at $340 million at its later-stage round in Apr 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Atsena Therapeutics raised?
Atsena Therapeutics has raised $238 million across 4 recorded rounds since 2020. The largest was a $90 million later-stage round in Mar 2025.
Atsena Therapeutics has filed 4 Form Ds with the SEC since 2020, most recently in Apr 2025 ($90 million sold to 14 investors).
Atsena Therapeutics investors
12 investors are on record for Atsena Therapeutics, including Wellington Management, Bain Capital, Osage University Partners and Hatteras Venture Partners. By type, the record holds 3 venture capital firms, 1 asset manager and 1 private equity firm. The later-stage round in Mar 2025 drew 14 investors.
About Atsena Therapeutics
Developer of ocular gene therapies designed to reverse or prevent blindness. The company's programs include treatments for leading forms of Leber congenital amaurosis and Usher syndrome and have a pipeline powered by associated virus technology, enabling healthcare professionals to reverse or prevent blindness and overcome the hurdles presented by inherited retinal disease.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2019
- Employees
- 32
- Website
- atsenatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.